Effect of esketamine for preventing postpartum depression based on GABAA receptor genes: a randomized controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046049

Enrollment

Unknown

Registered

2021-05-03

Start date

2021-05-06

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

caesarean section

Interventions

Experimental group:Esketamine

Control group:Placebo

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective cesarean section; 2. ASA I-II, aged >= 18 years; 3. The body mass index is 15-30 kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Mental illness; 2. Serious obstetric complications or serious underlying diseases; 3. Allergy to esketamine; 4. Intraspinal anesthesia is contraindicated.

Design outcomes

Primary

Measure	Time frame
incidence of postpartum depression;	—

Secondary

Measure	Time frame
NRS scores at different time after surgery;GABAA receptor genes;	—

Countries

China

Contacts

Public ContactLiu Qingren

Wuxi City Xishan People's Hospital

liuqr5250@163.com+86 13601510412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026